SCR7, an inhibitor of NHEJ can sensitize tumor cells to ionization radiation
Nonhomologous end joining (NHEJ), one of the major DNA double‐strand break repair
pathways, plays a significant role in cancer cell proliferation and resistance to radio and …
pathways, plays a significant role in cancer cell proliferation and resistance to radio and …
Autocyclized and oxidized forms of SCR 7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner
Nonhomologous DNA end joining (NHEJ) is the major DNA double‐strand break (DSB)
repair pathway in mammals. Previously, we have described a small molecule inhibitor, SCR …
repair pathway in mammals. Previously, we have described a small molecule inhibitor, SCR …
Identification and characterization of novel SCR7‐based small‐molecule inhibitor of DNA end‐joining, SCR130 and its relevance in cancer therapeutics
Targeting DNA repair with small‐molecule inhibitors is an attractive strategy for cancer
therapy. Majority of DNA double‐strand breaks in mammalian cells are repaired through …
therapy. Majority of DNA double‐strand breaks in mammalian cells are repaired through …
Non-homologous DNA end joining in anticancer therapy
E Pastwa, M Malinowski - Current cancer drug targets, 2007 - benthamdirect.com
Non-homologous DNA end joining (NHEJ) is the major pathway for the repair of double-
strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become …
strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become …
Water-soluble version of SCR7-pyrazine inhibits DNA repair and abrogates tumor cell proliferation
Aim: Mammalian DNA Ligases play pivotal role in processes such as DNA replication,
recombination, and repair, which qualifies them as potent therapeutic targets to eradicate …
recombination, and repair, which qualifies them as potent therapeutic targets to eradicate …
Inhibitor of nonhomologous end joining can inhibit proliferation of diffuse large B-cell lymphoma cells and potentiate the effect of ionization radiation
V Gopalakrishnan, G Radha… - Journal of Radiation …, 2018 - journals.lww.com
Aim: Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive type of
non-Hodgkin's lymphoma that accounts for~ 40% of all lymphomas. DLBCL is considered to …
non-Hodgkin's lymphoma that accounts for~ 40% of all lymphomas. DLBCL is considered to …
SCR7, a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end‐joining
Background DNA double‐strand breaks (DSBs) are harmful to the cell as it could lead to
genomic instability and cell death when left unrepaired. Homologous recombination and …
genomic instability and cell death when left unrepaired. Homologous recombination and …
The PI3K/mTOR inhibitor ompalisib suppresses nonhomologous end joining and sensitizes cancer cells to radio-and chemotherapy
J Du, F Chen, J Yu, L Jiang, M Zhou - Molecular Cancer Research, 2021 - AACR
As the predominant pathway for the repair of DNA double-strand breaks (DSB), non-
homologous end joining (NHEJ) attenuates the efficacy of cancer treatment which relies on …
homologous end joining (NHEJ) attenuates the efficacy of cancer treatment which relies on …
[HTML][HTML] An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression
DNA Ligase IV is responsible for sealing of double-strand breaks (DSBs) during
nonhomologous end-joining (NHEJ). Inhibiting Ligase IV could result in amassing of DSBs …
nonhomologous end-joining (NHEJ). Inhibiting Ligase IV could result in amassing of DSBs …
Identification and characterization of mercaptopyrimidine‐based small molecules as inhibitors of nonhomologous DNA end joining
Mercaptopyrimidine derivatives are heterocyclic compounds with potent biological activities
including antiproliferative, antibacterial, and anti‐inflammatory properties. The present study …
including antiproliferative, antibacterial, and anti‐inflammatory properties. The present study …